Our MyoCAT instrument comprises a suite of computerised adaptive tests (CATs) that measure the impact of myopia (simple, high and pathologic) and associated vision impairment on 7 domains of quality of life.
With a user-friendly interface and automated feedback system, MyoCAT offers researchers, clinicians and clinical trial teams a precise and efficient PROM to evaluate the effectiveness of treatments and interventions, including spectacles, contact lenses, and refractive surgery such as LASIK and SMILE, from the patient’s perspective.
MyoCAT is currently under development and is anticipated to be available in 2023.
Publications
Domain and item development and refinement
Qualitative interviews with patients and experts in the field.
Pilot testing
Psychometric testing of item banks in a large sample of patients across the spectrum of myopia.